Current Journal of Neurology

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Peer Review Process

Journal Metrics

News

Publication Ethics and Malpractice Statement

Epidemiological parameters of multiple sclerosis in Chaharmahal and Bakhtiari Province, Iran

Document Type : Original Article

Authors

1 Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

2 Department of Neurology, School of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran

Abstract

Background: Multiple sclerosis (MS) is a neurological disease with a high burden and disability. There are reports of various medications’ side effects on patients with MS. The aim of the study is to determine the characteristics and medicine usage distribution among patients with MS in Chaharmahal and Bakhtiari Province in Iran.
Methods: This registry-based cross-sectional study was performed among MS cases in Chaharmahal and Bakhtiari Province. The epidemiological data were collected from the nationwide MS registry of Iran (NMSRI) from 2019 to 2022. The information collected included age, sex, family history, type of MS, age at MS onset and diagnosis, MS symptoms, physical condition, and history of medication use. All tests were performed at a significance level of 0.05 using SPSS software.
Results: A total of 416 patients included in this study. Among them, 325 individuals (78%) were women with mean ± standard deviation (SD) of age of 37.35 ± 8.51 years. No significant difference was observed between men and women in terms of age, type of MS disease, family history of MS, and physical condition (P > 0.05). The results showed that the Expanded Disability Status Scale (EDSS) score in female patients (1.41) was different from the EDSS score in male patients (1.77) (P < 0.05). Most of the patients often used interferon beta (IFN-β).
Conclusion: The results provided new insight into the epidemiology and medicine patterns of patients with MS in Chaharmahal and Bakhtiari Province. The epidemiological situation of MS in this province is similar to other parts of Iran. Planning according to national programs is suggested for the management and control of MS.

Keywords

References
  1. Dehghani R, Yunesian M, Sahraian MA, Gilasi HR, Kazemi M, V. The Evaluation of multiple sclerosis dispersal in iran and its association with urbanization, life style and industry. Iran J Public Health 2015; 44(6): 830-8.
  2. Ramsaransing GS, De Keyser J. Benign course in multiple sclerosis: A review. Acta Neurol Scand 2006; 113(6): 359-69.
  3. Greer JM, McCombe PA. Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms. J Neuroimmunol 2011; 234(1-2): 7-18.
  4. Correale J, Marrodan M, Ysrraelit MC. Mechanisms of neurodegeneration and axonal dysfunction in progressive multiple sclerosis. Biomedicines 2019; 7(1): 14.
  5. Ellwardt E, Zipp F. Molecular mechanisms linking neuroinflammation and neurodegeneration in MS. Exp Neurol 2014; 262 Pt A: 8-17.
  6. Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler 2020; 26(14): 1816-21.
  7. Eskandarieh S, Sahraian M. Epidemiological evidence of the recent surge in MS in Asia and Australia: A systematic review. J Kermanshah Univ Med Sci 2021; 25(2): e111028.
  8. Sahraian MA, Naser Moghadasi A, Eskandarieh S. Economic sanctions against Iran as an important factor in threatening the health of patients with multiple sclerosis. Curr J Neurol 2021; 20(1): 15-22.
  9. Etemadifar M, Sajjadi S, Nasr Z, Firoozeei TS, Abtahi SH, Akbari M, et al. Epidemiology of multiple sclerosis in Iran: A systematic review. Eur Neurol 2013; 70(5-6): 356-63.
  10. Etemadifar M, Mehrabi B, Kiani-Peykani R, Abtahi SH, Nekouie-Isfahani K, Ramagopalan SV, et al. Soil heavy metals are associated with the distribution of multiple sclerosis in Isfahan, Iran. Acta Neurol Scand 2016; 134(4): 292-9.
  11. Azami M, YektaKooshali MH, Shohani M, Khorshidi A, Mahmudi L. Epidemiology of multiple sclerosis in Iran: A systematic review and meta-analysis. PLoS One 2019; 14(4): e0214738.
  12. Pakdel M, Karin HA, Bidkhori M, Hadei M, Kazemi M, V, Sarmadi M, et al. Do socioeconomic factors affect the prevalence of multiple sclerosis in Iran? Acta Neurol Scand 2019; 140(5): 328-35.
  13. Elhami SR, Mohammad K, Sahraian MA, Eftekhar H. A 20-year incidence trend (1989-2008) and point prevalence (March 20, 2009) of multiple sclerosis in Tehran, Iran: A population-based study. Neuroepidemiology 2011; 36(3): 141-7.
  14. Cheraghmakani H, Baghbanian SM, HabibiSaravi R, Azar A, Ghasemihamedani F. Age and sex-adjusted incidence and yearly prevalence of multiple sclerosis (MS) in Mazandaran province, Iran: An 11-years study. PLoS One 2020; 15(7): e0235562.
  15. Rezaeimanesh N, Moghadasi AN, Sahraian MA, Eskandarieh S. Dietary risk factors of primary progressive multiple sclerosis: A population-based case-control study. Mult Scler Relat Disord 2021; 56: 103233.
  16. Maroufi H, Mortazavi SH, Sahraian MA, Eskandarieh S. Environmental risk factors of multiple sclerosis in the Middle East and North Africa region: A systematic review. Curr J Neurol 2021; 20(3): 166-84.
  17. Shahin S, Eskandarieh S, Moghadasi AN, Razazian N, Baghbanian SM, Ashtari F, et al. Multiple sclerosis national registry system in Iran: Validity and reliability of a minimum data set. Mult Scler Relat Disord 2019; 33: 158-61.
  18. Ezabadi SG, Sahraian MA, Maroufi H, Shahrbaf MA, Eskandarieh S. Global assessment of characteristics of multiple sclerosis registries; A systematic review. Mult Scler Relat Disord 2022; 63: 103928.
  19. Salehi Z, Almasi-Hashiani A, Sahraian MA, Ashtari F, Baghbanian SM, Razazian N, et al. Epidemiology of familial multiple sclerosis in Iran: A national registry-based study. BMC Neurol 2022; 22(1): 76.
  20. Ghadiri F, Sahraian MA, Baghbanian SM, Ashtari F, Razazian N, Majdinasab N, et al. Prescription trends of disease-modifying treatments for multiple sclerosis in Iran over the past 30 years. Mult Scler Relat Disord 2022; 61: 103777.
  21. Mirmosayyeb O, Shaygannejad V, Bagherieh S, Hosseinabadi AM, Ghajarzadeh M. Prevalence of multiple sclerosis (MS) in Iran: A systematic review and meta-analysis. Neurol Sci 2022; 43(1): 233-41.
  22. Razazian N, Eskandarieh S, Siabani S, Afshari D, Sahraian MA, Khezri O, et al. Prevalence of multiple sclerosis and its clinical and demographic characteristics in Kurdish populations in western Iran (2020). Mult Scler Relat Disord 2022; 57: 103441.
  23. Kapica-Topczewska K, Brola W, Fudala M, Tarasiuk J, Chorazy M, Snarska K, et al. Prevalence of multiple sclerosis in Poland. Mult Scler Relat Disord 2018; 21: 51-5.
  24. Eliasdottir O, Kjartansson O, Olafsson E. Prevalence of multiple sclerosis in Iceland. Neuroepidemiology 2018; 51(1-2): 50-6.
  25. Nasiri M, Maroufi H, Sahraian MA, Eskandarieh S. Prevalence of multiple sclerosis and its risks in Tehran, Iran, in 2019. Neurol Sci 2021; 42(6): 2575-6.
  26. Orton SM, Herrera BM, Yee IM, Valdar W, Ramagopalan SV, Sadovnick AD, et al. Sex ratio of multiple sclerosis in Canada: A longitudinal study. Lancet Neurol 2006; 5(11): 932-6.
  27. Sharafaddinzadeh N, Moghtaderi A, Majdinasab N, Dahmardeh M, Kashipazha D, Shalbafan B. The influence of ethnicity on the characteristics of multiple sclerosis: A local population study between Persians and Arabs. Clin Neurol Neurosurg 2013; 115(8): 1271-5.
  28. Eskandarieh S, Heydarpour P, Minagar A, Pourmand S, Sahraian MA. Multiple sclerosis epidemiology in East Asia, South East Asia and South Asia: A systematic review. Neuroepidemiology 2016; 46(3): 209-21.
  29. Al-Abdullah MS, Siddiqui AF. Demographic and disease characteristics of multiple sclerosis in the Southwest Region of Saudi Arabia. Neurosciences (Riyadh) 2018; 23(4): 320-5.
  30. Radmehr M, Meghdadi S, Bahmanzadeh M, Sabbagh S. Prevalence, demographics and clinical characteristics of multiple sclerosis in North of Khuzestan Province, Iran. Jentashapir J Health Res 2015; 6(5): e23831.
  31. Deleu D, Mir D, Al Tabouki A, Mesraoua R, Mesraoua B, Akhtar N, et al. Prevalence, demographics and clinical characteristics of multiple sclerosis in Qatar. Mult Scler 2013; 19(6): 816-9.
  32. Ineichen BV, Schneider MP, Hlavica M, Hagenbuch N, Linnebank M, Kessler TM. High EDSS can predict risk for upper urinary tract damage in patients with multiple sclerosis. Mult Scler 2018; 24(4): 529-34.
  33. Berger T, Adamczyk-Sowa M, Csepany T, Fazekas F, Hojs FT, Horakova D, et al. Management of multiple sclerosis patients in central European countries: Current needs and potential solutions. Ther Adv Neurol Disord 2018; 11: 1756286418759189.
  34. Kapica-Topczewska K, Collin F, Tarasiuk J, Chorazy M, Czarnowska A, Kwasniewski M, et al. Clinical and epidemiological characteristics of multiple sclerosis patients receiving disease-modifying treatment in Poland. Neurol Neurochir Pol 2020; 54(2): 161-8.
  35. Brancati S, Gozzo L, Longo L, Vitale DC, Drago F. Rituximab in multiple sclerosis: Are we ready for regulatory approval? Front Immunol 2021; 12: 661882.
  36. Airas L, Nylund M, Mannonen I, Matilainen M, Sucksdorff M, Rissanen E. Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland. Mult Scler Relat Disord 2020; 40: 101980.
  37. Alldredge B, Jordan A, Imitola J, Racke MK. Safety and efficacy of Rituximab: Experience of a single multiple sclerosis center. Clin Neuropharmacol 2018; 41(2): 56-9.
  38. Cohan SL, Hendin BA, Reder AT, Smoot K, Avila R, Mendoza JP, et al. Interferons and multiple sclerosis: Lessons from 25 years of clinical and real-world experience with intramuscular interferon beta-1a (Avonex). CNS Drugs 2021; 35(7): 743-67.
  39. Bertolotto A, Gilli F. Interferon-beta responders and non-responders. A biological approach. Neurol Sci 2008; 29(Suppl 2): S216-S217.
  40. Fattahi M, Eskandari N, Sotoodehnejadnematalahi F, Shaygannejad V, Kazemi M. Comparison of the expression of miR-326 between interferon beta responders and non-responders in relapsing-remitting multiple sclerosis. Cell J 2020; 22(1): 92-5.
  41. Filipi M, Jack S. Interferons in the treatment of multiple sclerosis: A clinical efficacy, safety, and tolerability update. Int J MS Care 2020; 22(4): 165-72.
  42. Bertolotto A, Malucchi S, Sala A, Orefice G, Carrieri PB, Capobianco M, et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: A follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 2002; 73(2): 148-53.
Current Journal of Neurology
Volume 22, Issue 2
April 2023
Pages 103-109
Files
Share
How to cite
Statistics